A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Clinical trial NCT04917809 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04917809
Sponsor: Memorial Sloan Kettering Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Bladder Cancer Recurrent Bladder Cancer FGFR3 Gene Mutation

Start date: 2022-02-17
Primary completion: 2026-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.